Tag: immuno-oncology
Personalized mRNA vaccine clears first phase 3 hurdle in melanoma
Merck and Moderna's personalized mRNA shot slowed melanoma recurrence in the first phase 3 win for a neoantigen therapy.
Merck and Moderna's personalized mRNA shot slowed melanoma recurrence in the first phase 3 win for a neoantigen therapy.